The identity of the buyer or buyers is not yet public. It remains unclear whether EQT intends to divest its entire stake or retain a minority position, and the transaction timeline has not been disclosed.
For healthcare investors and practitioners with exposure to Southeast Asian medical assets, this sale signals a potential shift in ownership and operational strategy at a major regional provider. The $600 million valuation offers a market benchmark for private healthcare valuations in Singapore and Malaysia. Attorneys advising on healthcare M&A, regulatory compliance, or cross-border transactions in the region should monitor the transaction's completion and any changes to HMI Medical's governance or licensing arrangements that may follow a change of control.